Copyright
©The Author(s) 2020.
World J Transplant. May 29, 2020; 10(5): 90-103
Published online May 29, 2020. doi: 10.5500/wjt.v10.i5.90
Published online May 29, 2020. doi: 10.5500/wjt.v10.i5.90
Table 3 Dosing recommendation for tacrolimus based on CYP3A5 phenotype[12]
| CYP3A5 phenotype | Implications for tacrolimus pharmacologic measures | Therapeutic recommendations | Classification of recommendation |
| Extensive metabolizer (CYP3A5 expresser) | Lower dose-adjusted trough concentrations of TAC and decreased chance of achieving target TAC concentrations | Increase starting dose to 1.5-2 times recommended starting dose. Use therapeutic drug monitoring to guide dose adjustments | Strong |
| Intermediate metabolizer (CYP3A5 expresser) | Lower dose-adjusted trough concentrations of TAC and decreased chance of achieving target TAC concentrations | Increase starting dose to 1.5-2 times recommended starting dose. Use therapeutic drug monitoring to guide dose adjustments | Strong |
| Poor metabolizer (CYP3A5 non expresser) | Higher dose-adjusted trough concentrations of TAC and increased chance of achieving target TAC concentrations | Initiate therapy with standard recommended dose. Use therapeutic drug monitoring to guide dose adjustments | Strong |
- Citation: Salvadori M, Tsalouchos A. Pharmacogenetics of immunosuppressant drugs: A new aspect for individualized therapy. World J Transplant 2020; 10(5): 90-103
- URL: https://www.wjgnet.com/2220-3230/full/v10/i5/90.htm
- DOI: https://dx.doi.org/10.5500/wjt.v10.i5.90